Braddock Syndrome

Braddock syndrome is a very rare birth-defect condition. It was first described in two siblings. Babies have a VACTERL-like association of multiple anomalies. “VACTERL” means a non-random mix of defects that may involve the Vertebrae (spine), Anus, Cardiac (heart), Trachea-Esophagus, Renal (kidney), and Limb structures. In Braddock syndrome, this VACTERL-like picture occurs together with other findings such as pulmonary hypertension in the newborn, laryngeal webs, blue sclerae, abnormal ear shape, and persistent poor growth, while intelligence is reported as normal in the original description. Because so few patients have been reported, doctors still consider it an ultra-rare, poorly understood syndrome. monarchinitiative.org+3NCBI+3orpha.net+3

Braddock syndrome is an ultra-rare congenital condition reported in a single sibship and defined by a VACTERL-like pattern of anomalies along with pulmonary hypertension, laryngeal webs, blue sclerae, abnormal ears, persistent growth deficiency, and normal intellect. Inheritance has been considered probably autosomal recessive. Because so few cases exist, formal natural-history data and disease-specific trials are lacking; management is individualized and centers on early recognition and treatment of airway, cardiac, and pulmonary vascular complications. NCBI+1

VACTERL association is a non-random co-occurrence of vertebral, anal, cardiac, tracheo-esophageal, renal, and limb defects; children often need staged surgeries and coordinated, multidisciplinary follow-up. Braddock syndrome shows a VACTERL-like picture, but the specific cluster above (notably laryngeal webs and pulmonary hypertension) is what makes it distinct in the literature. orpha.net+2PMC+2

Important distinction: Braddock syndrome is not the same as Braddock–Carey syndrome (also called BRDCS). Braddock–Carey is a different disorder tied to a 21q22 microdeletion (involving RUNX1) and features like Pierre–Robin sequence, congenital thrombocytopenia, and agenesis of the corpus callosum. Some sites now group Braddock–Carey under “21q22.11-q22.12 microdeletion syndrome.” I mention this because the names sound similar in searches. malacards.org+4PubMed+4Wiley Online Library+4

Other names

• “VACTERL-like malformation syndrome with pulmonary hypertension and laryngeal webs” (descriptive phrase used in rare-disease catalogs). NCBI+1

• Catalog identifiers sometimes used for literature searches: MedGen C1842082, MONDO:0012032. NCBI+1

Types

There are no formal subtypes of Braddock syndrome because only a tiny number of cases have been published. Clinicians mainly use the core pattern (VACTERL-like anomalies + pulmonary hypertension + laryngeal web + blue sclerae + ear anomalies + growth failure with normal intellect) to recognize it. Related but distinct condition: Braddock–Carey syndrome (BRDCS1/BRDCS2) due to 21q22 microdeletions or rare KIF15 variants; this is a different disorder and should not be merged with Braddock syndrome. NCBI+3NCBI+3Wiley Online Library+3

Causes

What we know: The exact cause of Braddock syndrome is unknown. No single gene has been confirmed. Because the clinical picture overlaps with VACTERL association, researchers look at possible contributors known from VACTERL, airway-web, and neonatal pulmonary-hypertension research. The items below are plausible contributors or associations reported in related conditions; none are proven causes for Braddock syndrome itself due to the very small number of cases.

1. Multifactorial origin (gene + environment). Many VACTERL-pattern cases likely arise from combined genetic susceptibilities and environmental events during early organ formation. cincinnatichildrens.org

2. De novo genetic changes. New (not inherited) DNA variants are enriched in some VACTERL cohorts, suggesting a genetic contribution in some patients. PMC

3. Undetected chromosomal microdeletions/duplications. Some multi-system birth-defect patterns result from small chromosome losses or gains detectable by microarray/genome sequencing. (In the related Braddock–Carey syndrome, a 21q22 deletion is causal.) Wiley Online Library

4. Maternal pregestational diabetes. Diabetes is a known teratogenic state and has been linked to VACTERL-type constellations in observational studies. PubMed

5. Assisted reproductive technology (ART). Some data show higher VACTERL risk after ART conceptions. Mechanism is unclear. PMC

6. Maternal smoking. Case–control work suggests higher odds of VACTERL with maternal smoking. ResearchGate

7. Maternal overweight/obesity. Associations with VACTERL have been reported; the mechanism may involve metabolic and inflammatory pathways in early pregnancy. ResearchGate

8. Low periconceptional folate intake. Regular folic-acid use may reduce VACTERL risk; low intake may raise risk. ResearchGate

9. Early vascular disruption. Some VACTERL mechanisms are hypothesized to involve impaired blood flow to developing organs. jmg.bmj.com

10. Abnormal embryonic endoderm/mesoderm signaling. Developmental-biology models propose pathway disturbances that could yield the VACTERL mix. Ovid

11. Airway recanalization failure (laryngeal web). Laryngeal webs come from incomplete resorption of embryonic laryngeal epithelium; this can co-occur with other anomalies. orpha.net

12. 22q11.2 microdeletion association with laryngeal webs (differential). While not Braddock syndrome, 22q11.2 deletion is a known cause of laryngeal web and must be ruled out when webs are present. www.elsevier.com+1

13. Pulmonary vascular maladaptation (PPHN). Newborn pulmonary hypertension can follow abnormal lung vessel development or hypoxic stress around birth. In Braddock syndrome it is part of the reported picture. NCBI

14. Congenital diaphragmatic hernia or pulmonary hypoplasia (context for PPHN). These conditions reduce lung vascular beds and increase pulmonary pressure; they illustrate mechanisms relevant when PPHN accompanies multi-system defects. ucsfbenioffchildrens.org

15. Perinatal infection or inflammation (context for PPHN). Sepsis and pneumonia can worsen pulmonary vascular tone in newborns. Wiley Online Library

16. Medication exposures (e.g., SSRI late pregnancy) (PPHN context). Population data link late-pregnancy SSRI exposure with higher PPHN risk; relevance varies by case. revportcardiol.org

17. Unknown single-gene disorder(s). It remains possible that future sequencing will reveal one or more rare genes underlying Braddock syndrome. (This happened for the distinct Braddock–Carey syndrome series.) Wiley Online Library

18. Epigenetic effects. Changes in gene regulation during early development have been hypothesized in complex malformation patterns like VACTERL. Ovid

19. Maternal primiparity. First pregnancy was a statistical signal in a VACTERL case–control study; mechanism is uncertain. ResearchGate

20. Stochastic developmental error. Some complex malformations may reflect chance errors during organogenesis without a single fixed cause. Ovid

Symptoms and signs

Because Braddock syndrome is ultra-rare, doctors rely on the pattern:

1. Breathing trouble soon after birth. Due to pulmonary hypertension and/or laryngeal web narrowing the airway; babies may look blue and need oxygen. NCBI+1

2. Weak cry or hoarse voice. A laryngeal web can restrict vocal cord motion and change the voice at birth. orpha.net

3. Feeding difficulty or choking. If a tracheo-esophageal fistula or esophageal atresia is part of the VACTERL-like picture, feeds are hard and aspiration risk is high. Frontiers

4. Cyanosis (blue color). Poor oxygen due to PPHN or airway obstruction causes bluish lips and skin. NCBI

5. Abnormal ears. The original description highlights ear anomalies (shape/position). This may accompany hearing issues. NCBI

6. Blue sclerae. The “white” of the eyes looks bluish; reported in Braddock syndrome. NCBI

7. Poor growth (growth failure). Babies may remain small in weight and length over time. NCBI

8. Normal intellect in reported cases. Despite multiple physical anomalies, the original Braddock report notes normal intellectual development. NCBI

9. Vertebral/spinal anomalies. Scoliosis or malformed vertebrae can appear as part of a VACTERL-like pattern. Frontiers

10. Anal malformation. Anorectal malformations (e.g., imperforate anus) can be present. Frontiers

11. Heart defects. Septal defects or more complex cardiac anomalies may occur in the VACTERL spectrum. Frontiers

12. Trachea-esophageal anomalies. Fistula or atresia can produce cough with feeds and abdominal distention. Frontiers

13. Kidney/urinary anomalies. Renal dysplasia or reflux may be part of the pattern. Frontiers

14. Limb anomalies. Radial ray defects or other limb differences may be seen. Frontiers

15. Airway symptoms from laryngeal web. Stridor (noisy breathing), retractions, and recurrent laryngitis in infancy are classic for webs. PubMed

Diagnostic tests

Goal: confirm the pattern, assess airway and lungs, search for VACTERL-type anomalies, and exclude other named syndromes (especially 22q11.2 deletion and Braddock–Carey microdeletion).

A) Physical examination

1. Newborn general exam and vitals. Check breathing effort, oxygenation, perfusion, and growth percentiles; look for cyanosis or distress that suggests PPHN or airway obstruction. NCBI

2. Dysmorphology exam. Look carefully for blue sclerae, ear shape differences, facial features, and limb/spine anomalies to define the pattern. NCBI

3. Cardiovascular exam. Murmurs, gallops, or signs of pulmonary hypertension (loud P2) guide imaging and treatment. NCBI

4. Abdominal and perineal exam. Check for anal opening and fistula signs; look for masses suggesting renal anomalies. Frontiers

B) Manual/bedside tests

5. Pulse oximetry (pre- and post-ductal). Quick bedside oxygen test; a pre/post-ductal difference supports PPHN physiology. NCBI

6. Feeding/aspiration screen at bedside. Careful monitored trial or specialist-led swallow evaluation flags tracheo-esophageal issues needing imaging. Frontiers

7. Bedside airway assessment with gentle laryngoscopy (ENT). Visual inspection can reveal a laryngeal web; this is the key direct assessment. PubMed

8. Newborn hearing screen (OAE/ABR screen). Ear malformations increase the chance of hearing issues; early screening is standard. eScholarship

C) Laboratory and pathological tests

9. Arterial/Capillary blood gases. Evaluate oxygen and carbon dioxide levels in suspected PPHN. NCBI

10. Complete blood count and platelets. Baseline for newborn care; also helps differentiate Braddock (no thrombocytopenia expected) from Braddock–Carey (congenital thrombocytopenia). malacards.org

11. Infection markers (CRP, blood culture if indicated). Sepsis can worsen pulmonary pressures and must be treated quickly. Wiley Online Library

12. Metabolic panel and lactate. Check end-organ perfusion and metabolic stress in sick neonates. NCBI

13. Chromosomal microarray (CMA). First-line genomic test to look for pathogenic microdeletions/duplications; helps exclude 22q11.2 deletion (laryngeal web differential) and 21q22 microdeletion if Braddock–Carey is suspected. www.elsevier.com+1

14. Exome/genome sequencing (case-by-case). May reveal rare, novel variants in patients with complex malformations where CMA is normal. jmg.bmj.com

D) Electrodiagnostic tests

15. Electrocardiogram (ECG). Looks for right-ventricular strain or rhythm issues in pulmonary hypertension. NCBI

16. Auditory brainstem response (diagnostic ABR). Objective test for hearing pathway function when ear malformations are present. eScholarship

17. Continuous cardiorespiratory monitoring. In NICU, monitoring helps track oxygen saturation and heart rate trends in PPHN. NCBI

E) Imaging and endoscopic tests

18. Echocardiography. The key test for PPHN and structural heart disease; estimates pulmonary pressures and checks for shunts/defects. NCBI

19. Flexible/rigid laryngoscopy (and bronchoscopy as needed). Confirms laryngeal web type and thickness; guides surgery timing. PubMed

20. Spine and limb radiographs. Define vertebral segmentation defects, rib anomalies, or radial ray differences. Frontiers

21. Renal and urinary tract ultrasound. Screens for kidney malformations common in VACTERL-like patterns. Frontiers

22. Chest radiograph. Reviews lung parenchyma, line/tube positions, and heart size in respiratory distress. NCBI

23. Esophagram or fluoroscopic swallow study. Assesses tracheo-esophageal fistula or aspiration risk when suspected. Frontiers

24. Fetal ultrasound (prenatal) and targeted fetal echo (when history suggests). May detect some anomalies before birth in future pregnancies. Frontiers

Non-pharmacological treatments (therapies & others)

1. Multidisciplinary care pathway (neonatology + cardiology + pulmonology + ENT + anesthesia + rehab).
   A structured team approach improves detection of subtle malformations, times operations safely, and coordinates airway, heart, kidney, and limb evaluations. In VACTERL-type conditions, early surgical repair for critical defects (e.g., cardiac lesions) is common; in Braddock syndrome, early ENT and pulmonary hypertension teams are crucial. Purpose: organize care, reduce complications, and avoid delays. Mechanism: shared decision-making, synchronized surgical windows, and standardized monitoring (oxygenation, echocardiography, growth). Evidence from VACTERL cohorts and guideline frameworks underlines the importance of coordinated, staged intervention and long-term surveillance. PMC+1

2. Airway assessment & endoscopic lysis/stenting for laryngeal web (ENT).
   Congenital laryngeal webs can obstruct airflow and cause stridor, feeding difficulty, and respiratory distress. Thin webs may be treated endoscopically (cold knife/laser) with suturing or placement of a keel to prevent re-adhesion; thick webs may need open laryngofissure and temporary stenting. Purpose: relieve airway blockage and enable safe breathing and feeding. Mechanism: mechanically opens the anterior glottic web so air passes freely and vibration of the vocal folds is preserved as much as possible. Outcomes improve with careful selection, postoperative stenting, and voice therapy. Medscape+1

3. Pulmonary hypertension (PH) supportive measures (oxygen, supervised exercise, salt/fluid management).
   Supportive care in PAH includes oxygen if hypoxemic, thoughtful diuretics for fluid overload, and supervised pulmonary rehabilitation to build endurance without overstraining the right heart. Purpose: reduce right-heart stress and improve function and quality of life. Mechanism: oxygen raises blood oxygen levels; diuretics reduce congestion; guided exercise improves peripheral conditioning and ventilatory efficiency. Use under specialist guidance, especially in infants/children. PH Association+2American Lung Association+2

4. Early echocardiography and serial hemodynamic follow-up.
   Because pulmonary hypertension drives morbidity, early and repeat echocardiograms help monitor right-ventricular function and estimate pulmonary pressures; selected cases require right-heart catheterization for definitive diagnosis and therapy planning. Purpose: detect PH early, guide therapy, and track response. Mechanism: non-invasive imaging (and, when needed, catheter data) quantifies load on the heart and directs escalation (e.g., adding targeted PAH drugs). PubMed

5. Cardiac defect repair when present.
   VACTERL-like phenotypes can include cardiac anomalies; timely surgical or catheter-based repair can reduce pulmonary overcirculation and secondary PH. Purpose: correct anatomy to reduce strain. Mechanism: closing shunts or repairing valves normalizes hemodynamics and lowers pulmonary vascular injury risk. PMC

6. Feeding and growth optimization (nutritionist + speech/feeding therapy).
   Airway and breathing issues can impair feeding and growth. A tailored plan (thickened feeds if aspirating, high-calorie formulas, or temporary tube feeding) supports catch-up growth. Purpose: meet metabolic demands of chronic cardiopulmonary stress. Mechanism: ensures adequate calories/protein while minimizing aspiration risk and work of feeding. PMC

7. Vaccination & infection-prevention bundle.
   Children with PH and airway anomalies are vulnerable to severe respiratory infections. Keeping routine and respiratory vaccines up to date and using meticulous hand/respiratory hygiene reduces exacerbations. Purpose: prevent infection-triggered PH decompensation. Mechanism: immune priming and reduced pathogen exposure lower hospitalization risk. American Thoracic Society

8. ENT voice and airway therapy post-repair.
   Following web release, voice therapy and breathing techniques can improve phonation and reduce maladaptive straining while tissue heals. Purpose: restore safe voice and airflow. Mechanism: structured exercises encourage proper glottic function and reduce scarring. Medscape

9. Pulmonary rehabilitation (age-appropriate).
   In older children/adolescents with stable PH, supervised, individualized exercise (often low-to-moderate intensity) improves functional class and quality of life. Purpose: increase walking distance and daily activity tolerance. Mechanism: peripheral conditioning and improved ventilatory efficiency with careful monitoring. smw.ch

10. Home pulse-oximetry guidance for high-risk periods.
    Short-term home SpO₂ checks during illness or after therapy changes may help triage and prompt timely medical review. Purpose: early detection of hypoxemia. Mechanism: simple non-invasive monitoring triggers earlier intervention. American Thoracic Society

11. Respiratory physiotherapy & airway clearance techniques.
    When infections occur, chest physiotherapy and airway clearance can reduce atelectasis and help secretion mobilization. Purpose: maintain ventilation and reduce complications. Mechanism: mechanical techniques improve airflow and mucus transport. American Thoracic Society

12. Sleep assessment and nocturnal oxygen when indicated.
    If desaturation is present during sleep, nocturnal oxygen can support right-heart function. Purpose: limit hypoxic pulmonary vasoconstriction overnight. Mechanism: supplemental O₂ raises alveolar and arterial oxygen levels, lowering pulmonary vascular tone in hypoxemic patients. American Thoracic Society+1

13. High-risk anesthesia planning (airway + PH).
    Any procedure requires an anesthesia plan that anticipates a difficult airway (laryngeal web history) and PH (right-heart sensitivity). Purpose: prevent perioperative crises. Mechanism: tailored induction/ventilation strategies and invasive monitoring as needed. orphananesthesia.eu

14. Psychosocial support for family and child.
    Rare-disease care is stressful; counseling and support groups (PH associations) improve coping and adherence. Purpose: reduce anxiety, improve quality of life. Mechanism: education, peer support, and care navigation. PH Association

15. Dental/airway precautions.
    Airway anomalies and cardiac conditions alter procedural risk; dental teams should plan with anesthesia and cardiology input. Purpose: safe dental care. Mechanism: pre-op assessment, prophylaxis when indicated, and careful airway plans. johs.com.sa

16. Right-heart-protective lifestyle (avoid high altitude, smoking exposure).
    Avoid hypoxia triggers and secondhand smoke to reduce pulmonary vasoconstriction. Purpose: prevent PH worsening. Mechanism: minimize environmental hypoxemia and irritants. Mayo Clinic

17. Education on medication interactions (especially with PH drugs).
    Families should learn which OTC/herbal products interact with PAH therapies and when to call the team. Purpose: avoid adverse effects. Mechanism: reduces hypotension/bleeding risks and drug–drug interactions. PH Association

18. Genetic counseling.
    While evidence is sparse, the original report suggested likely autosomal recessive inheritance; counseling helps with family planning and anticipatory guidance. Purpose: inform recurrence risk and testing options. Mechanism: pedigree review and discussion of uncertainty. NCBI

19. Transition planning to adult PH/ENT care.
    As children age, formal transition improves continuity and adherence. Purpose: sustained outcomes. Mechanism: handover protocols and patient self-management skills. PH Association

20. Emergency action plan.
    Families should have a written plan for respiratory distress or syncope episodes. Purpose: timely triage. Mechanism: stepwise response and when to call EMS. American Thoracic Society

---

Drug treatments

Important: These medicines do not “treat Braddock syndrome itself.” They treat pulmonary arterial hypertension (PAH) or its consequences when present. Doses/timing must be set by specialists and adjusted for age, weight, organ function, and drug interactions.

1. Bosentan (Tracleer®, ERA).
   Purpose: Lower pulmonary vascular resistance and improve exercise capacity. Mechanism: Dual endothelin-A/B receptor blockade reduces vasoconstriction and proliferation. Dose/Timing: Weight-based in pediatrics; adult typical 62.5 mg twice daily → 125 mg twice daily; strict REMS for teratogenicity; monitor LFTs and hemoglobin. Side effects: Hepatotoxicity, edema, anemia, teratogenicity; CYP interactions. Use only in specialized centers. FDA Access Data+1

2. Ambrisentan (Letairis®, ERA).
   Purpose: Improve exercise capacity and delay clinical worsening in PAH. Mechanism: Selective endothelin-A receptor antagonism. Dose/Timing: Adults 5–10 mg once daily; pregnancy contraindicated; monthly testing required. Side effects: Peripheral edema, anemia, nasal congestion; embryo-fetal toxicity boxed warning. FDA Access Data+1

3. Macitentan (Opsumit®, ERA).
   Purpose: Reduce risk of PAH progression and hospitalization. Mechanism: Dual ERA with high tissue penetration. Dose/Timing: Adults 10 mg once daily; teratogenic; monitor for anemia and liver issues. Side effects: Nasopharyngitis, headache, anemia; contraindicated in pregnancy. FDA Access Data+1

4. Sildenafil (Revatio®, PDE-5 inhibitor).
   Purpose: Improve exercise ability and delay clinical worsening. Mechanism: Inhibits PDE-5 → augments nitric-oxide–cGMP signaling → vasodilation in pulmonary vasculature. Dose/Timing: Adult oral 20 mg TID (IV available); caution with nitrates/alpha-blockers; avoid with riociguat. Side effects: Headache, flushing, hypotension, visual changes. FDA Access Data

5. Tadalafil (Adcirca®, PDE-5 inhibitor).
   Purpose: Improve exercise capacity in PAH. Mechanism: PDE-5 inhibition (longer-acting). Dose/Timing: Adults typically 40 mg once daily; contraindicated with riociguat; adjust for renal/hepatic impairment. Side effects: Headache, dyspepsia, myalgia, hypotension; rare hypersensitivity. FDA Access Data

6. Riociguat (Adempas®, soluble guanylate cyclase stimulator).
   Purpose: Improve exercise capacity and hemodynamics in PAH and inoperable/persistent CTEPH. Mechanism: Directly stimulates sGC and sensitizes it to NO → ↑cGMP → vasodilation/antiproliferation. Dose/Timing: Titrated TID; do not combine with PDE-5 inhibitors; strong pregnancy boxed warning and REMS. Side effects: Hypotension, headache, GERD, dizziness. FDA Access Data+1

7. Epoprostenol (Flolan®, Veletri®, prostacyclin).
   Purpose: For high-risk PAH; improves symptoms and survival in advanced disease. Mechanism: Potent vasodilator and inhibitor of platelet aggregation via IP receptor. Dose/Timing: Continuous IV infusion with careful up-titration and dedicated line. Side effects: Flushing, headache, jaw pain, hypotension; catheter complications. FDA Access Data+1

8. Treprostinil (Remodulin® – IV/SC; Tyvaso® – inhaled; oral forms exist).
   Purpose: Improve exercise capacity and symptoms. Mechanism: Prostacyclin analogue (IP receptor agonist). Dose/Timing: Route-specific titration; inhaled Tyvaso given in sessions daily. Side effects: Infusion site pain (SC), cough (inhaled), headache, hypotension. FDA Access Data+2FDA Access Data+2

9. Iloprost (Ventavis®, inhaled prostacyclin).
   Purpose: Improve exercise capacity and symptoms in PAH with frequent inhalations. Mechanism: Prostacyclin analogue causing selective pulmonary vasodilation. Dose/Timing: Multiple inhalations per day via specific device. Side effects: Cough, flushing, jaw pain, hypotension. FDA Access Data+1

10. Combination therapy (ERA + PDE-5i or sGC) per guidelines.
    Purpose: Target multiple pathways (endothelin, NO–cGMP) for better outcomes. Mechanism: Synergistic reduction in vascular tone/proliferation. Dose/Timing: Specialist-directed; watch for hypotension and interactions; avoid PDE-5i with riociguat. Side effects: Additive edema/hypotension, anemia risks. PubMed+1

11. Diuretics (e.g., furosemide) for right-heart failure congestion.
    Purpose: Reduce edema/hepatic congestion and breathlessness in fluid-overloaded PH. Mechanism: Natriuresis reduces preload and venous congestion. Dose/Timing: Weight-based, carefully titrated; monitor electrolytes/renal function. Side effects: Hypokalemia, dehydration, kidney dysfunction. American Lung Association

12. Anticoagulation (selected cases only).
    Purpose: Reduce thrombosis risk in some PH phenotypes or with central lines. Mechanism: Inhibits coagulation pathways. Dose/Timing: Highly individualized; weigh bleeding risk. Side effects: Bleeding, drug interactions. PH Association

13. Digoxin (selected patients with right-heart failure/arrhythmias).
    Purpose: Symptom relief in certain PH patients with RV dysfunction/AF. Mechanism: Positive inotropy and rate control. Dose/Timing: Narrow therapeutic window; monitor levels. Side effects: Arrhythmias, GI upset, visual changes. American Lung Association

14. Supplemental oxygen (when hypoxemic).
    Purpose: Reduce hypoxic pulmonary vasoconstriction and relieve symptoms. Mechanism: Increases PaO₂ → lowers pulmonary vascular tone in hypoxemia. Dose/Timing: Titrated to maintain target saturations; nocturnal or continuous per need. Side effects: Dryness, rare CO₂ retention (monitor). PubMed+1

15. Iron repletion (if iron-deficient).
    Purpose: Improve exercise capacity where iron deficiency worsens PH symptoms. Mechanism: Restores hemoglobin/oxygen delivery; may influence skeletal muscle function. Dose/Timing: Oral or IV depending on tolerance. Side effects: GI upset (oral), infusion reactions (IV). PubMed

16. Vaccinations-associated prophylaxis (e.g., palivizumab policies not disease-specific).
    Purpose: Reduce severe viral lower respiratory infections that can decompensate PH. Mechanism: Immune priming/passive immunization per pediatric guidelines/eligibility. Dose/Timing: Per age/seasonal recommendations. Side effects: Injection-site reactions. American Thoracic Society

17. Proton-pump inhibitor/H₂ blocker (reflux-related airway irritability).
    Purpose: Reduce reflux microaspiration that can worsen airway symptoms. Mechanism: Acid suppression decreases inflammation from refluxate. Dose/Timing: Standard pediatric/adult dosing; reassess need. Side effects: Headache, GI changes. Medscape

18. Inhaled bronchodilators for reactive airway episodes (not as PH therapy).
    Purpose: Relieve bronchospasm during infections. Mechanism: β₂-agonism relaxes airway smooth muscle. Dose/Timing: PRN per symptoms. Side effects: Tachycardia, tremor. American Thoracic Society

19. Antibiotics for proven bacterial respiratory infections.
    Purpose: Treat pneumonia/tracheobronchitis promptly to prevent PH worsening. Mechanism: Pathogen-targeted therapy. Dose/Timing: Per culture/local guidelines. Side effects: Drug-specific. American Thoracic Society

20. Escalation to advanced prostacyclin combinations in high-risk PAH.
    Purpose: Improve survival and functional capacity when single-pathway therapy fails. Mechanism: Add parenteral/inhaled prostacyclin to ERA/PDE-5i backbone under expert care. Dose/Timing: Specialist titration. Side effects: As above, plus line/device issues. PubMed

---

Dietary molecular supplements

Use only with the clinical team; avoid interactions with PAH drugs and anticoagulants.

1. Omega-3 fatty acids.
   Can modestly reduce systemic inflammation and support endothelial function; in chronic cardiopulmonary disease, they may aid general cardiovascular health. Purpose: adjunctive heart-healthy support. Mechanism: membrane lipid modulation and anti-inflammatory eicosanoids. Note: monitor with anticoagulants. American Thoracic Society

2. Vitamin D.
   Deficiency is common in chronic illness and may impact muscle function and immunity; replacing deficiency supports overall health and activity capacity. Purpose: correct deficiency. Mechanism: nuclear receptor effects on muscle and immune cells. American Thoracic Society

3. Iron (when deficient).
   In PH, iron deficiency can worsen exercise tolerance; supervised repletion can help. Purpose: improve oxygen delivery. Mechanism: hemoglobin synthesis and mitochondrial enzymes. PubMed

4. Magnesium.
   May help if diuretics cause losses or if cramps occur. Purpose: correct depletion. Mechanism: electrolyte balance and muscle function. American Thoracic Society

5. Coenzyme Q10.
   Sometimes used for general mitochondrial support in chronic cardiac conditions, though evidence is mixed; discuss with cardiology. Purpose: energy metabolism support. Mechanism: electron transport chain cofactor. American Thoracic Society

6. Protein/calorie supplementation.
   In growth-restricted children, high-calorie formulas or modular supplements support catch-up growth. Purpose: meet increased metabolic needs. Mechanism: ensures adequate substrates for growth and healing. PMC

7. Electrolyte solutions during illness.
   Prevents dehydration that can destabilize PH. Purpose: maintain volume/electrolytes. Mechanism: oral rehydration with balanced salts. American Thoracic Society

8. Antioxidant-rich foods (berries/leafy greens).
   General cardiopulmonary wellness; avoid “mega-dose” supplements without guidance. Purpose: diet quality. Mechanism: polyphenols and micronutrients. American Thoracic Society

9. Sodium moderation.
   Supports diuretic effect and reduces edema in right-heart failure. Purpose: less fluid retention. Mechanism: lower sodium → lower extracellular volume. American Lung Association

10. Caffeine caution.
    Excess may worsen palpitations/anxiety; modest intake is often tolerated but ask your team. Purpose: avoid triggers. Mechanism: adenosine receptor antagonism → tachycardia potential. American Thoracic Society

(Dosages for vitamins/minerals should match age-specific reference ranges and lab-guided targets; your clinicians will individualize them.) American Thoracic Society

---

Immunity-booster / Regenerative / Stem cell drugs

Key truth: There are no FDA-approved stem-cell drugs for pulmonary hypertension or for Braddock syndrome; stem-cell therapies remain experimental in early trials. Families should avoid commercial “stem cell clinics.” Below is what to know: PH Association+2American Thoracic Society+2

1. Routine immunizations (age-appropriate vaccines).
   Function: Reduce severe respiratory infections that can destabilize PH. Mechanism: Immune priming lowers infection-triggered decompensation. Dosage: Per national schedules. Note: Not a drug for Braddock syndrome per se, but essential preventive “immune support.” American Thoracic Society

2. Palivizumab (RSV prophylaxis, eligibility-based).
   Function: Monoclonal antibody during RSV season in certain high-risk infants; can reduce severe RSV disease and hospitalization. Mechanism: Neutralizes RSV F protein. Dosage: Weight/season protocols. Note: Use per pediatric criteria. American Thoracic Society

3. Iron repletion when deficient (immune & exercise support).
   Function: Correct anemia that worsens PH symptoms and infection tolerance. Mechanism: Restores hemoglobin/immune enzyme function. Dosage: Lab-guided. PubMed

4. Mesenchymal stem cells (MSCs) — experimental only.
   Function: Investigational for PAH to repair pulmonary vascular injury. Mechanism: Paracrine anti-inflammatory and endothelial-restorative effects in models. Status: Preclinical/early clinical studies; not FDA-approved. Caution: Seek trials, avoid commercial clinics. PMC+1

5. Endothelial progenitor cells — experimental.
   Function: Aim to regenerate pulmonary endothelium. Mechanism: Homing to lung vasculature and pro-angiogenic signaling. Status: Early trials; safety/efficacy not established for routine care. jhltonline.org

6. Exosome-based therapies — experimental.
   Function: Cell-free vesicles carrying reparative signals. Mechanism: Modulate inflammation, apoptosis, and vascular remodeling in models. Status: Research-stage; no FDA approval for PH. e-kcj.org

---

Surgeries

1. Endoscopic laryngeal web lysis ± keel/stent.
   Why: Relieve airway obstruction and improve breathing/voice. How: Endoscopic incision of the web; a keel/stent or sutures prevent re-adhesion; thick webs may require open laryngofissure. Medscape+1

2. Cardiac surgery/catheter interventions (if structural lesion present).
   Why: Correct shunts/valvular lesions driving PH or heart failure. How: Defect-specific repair to normalize hemodynamics. PMC

3. Airway stenting (selected complex stenosis).
   Why: Maintain airway patency where collapse/stenosis recurs or is complex. How: Temporary laryngeal/tracheal stents under endoscopic guidance with close follow-up. NCBI

4. Tracheostomy (rare, last resort).
   Why: Secure airway in refractory obstruction/complex webs. How: Surgical airway with meticulous care and long-term ENT follow-up. Medscape

5. Lung/heart-lung transplantation (extremely rare in children with refractory PAH).
   Why: Salvage therapy in end-stage PAH after maximal medical therapy. How: Referral to transplant center per pediatric PH guidelines. PubMed

---

Preventions

1. Keep vaccines current; prevent respiratory infections that worsen PH. American Thoracic Society

2. Avoid secondhand smoke and high-altitude exposure to reduce hypoxic triggers. Mayo Clinic

3. Follow growth-nutrition plans to counter persistent growth deficiency. PMC

4. Practice hand hygiene and illness-season precautions. American Thoracic Society

5. Maintain scheduled echo/clinic follow-ups for early PH detection. PubMed

6. Use supervised exercise/rehab only; avoid overexertion without guidance. smw.ch

7. Learn drug interaction warnings for PAH meds (e.g., no PDE-5i + riociguat). FDA Access Data

8. Have an anesthesia/airway plan on file before procedures. orphananesthesia.eu

9. Seek genetics counseling for family planning. NCBI

10. Avoid unregulated “stem cell clinics”; enroll only in legitimate trials if offered. PH Association

---

When to see doctors (or go to the ER)

Seek urgent care for noisy/stridorous breathing, persistent cyanosis or low oxygen readings, fainting/syncope, rapidly worsening shortness of breath, fever with breathing difficulty, or new leg/abdominal swelling. These can signal airway obstruction or PH decompensation requiring immediate intervention. For routine care, keep cardiology/PH, ENT, and pediatric visits on schedule for growth checks, echo monitoring, medication safety labs (e.g., ERAs need LFT/hemoglobin monitoring and pregnancy precautions), and therapy adjustments as your child grows. Medscape+1

---

What to eat & what to avoid

1. Small, frequent, nutrient-dense meals to meet higher energy needs without tiring; add healthy fats and proteins as advised. PMC

2. Moderate sodium to help control edema if diuretics are used. American Lung Association

3. Adequate fluids but avoid over-hydration; follow PH team guidance. American Thoracic Society

4. Iron-rich foods (if deficient) and vitamin C–rich produce to aid absorption. PubMed

5. Vitamin D sources or supplements if low, per labs. American Thoracic Society

6. High-fiber fruits/vegetables for general health and to avoid constipation strain. American Thoracic Society

7. Limit ultra-processed, high-salt snacks that worsen fluid retention. American Lung Association

8. Be cautious with herbal/OTC products that interact with PAH drugs or anticoagulants. PH Association

9. Avoid excess caffeine/energy drinks which may raise heart rate or anxiety. American Thoracic Society

10. During illness, use oral rehydration solutions as advised to prevent dehydration. American Thoracic Society

---

Frequently asked questions (FAQs)

1) Is there a cure for Braddock syndrome?
No. Care focuses on treating associated problems (especially pulmonary hypertension and airway anomalies) using established pediatric, PH, and ENT standards. Early recognition and team care are key for best outcomes. NCBI+1

2) How common is it?
Extremely rare; the MedGen/Orphanet record describes only two siblings in the original report, which explains why evidence is limited and extrapolated from related conditions. NCBI+1

3) What’s the biggest risk to watch for?
Airway compromise from laryngeal web and pulmonary hypertension affecting the right heart. Any noisy breathing, low oxygen, syncope, or rapid breathing needs urgent assessment. Medscape+1

4) Can oxygen therapy help?
Yes, if there’s low blood oxygen. Oxygen reduces hypoxic pulmonary vasoconstriction and symptoms; it isn’t used routinely unless hypoxemia is present. PubMed

5) Do PAH pills fix the airway problem?
No. PH drugs act on blood vessels; laryngeal webs need ENT procedures and therapy. Many children need both teams involved. Medscape

6) Which PAH medicines are most used?
Guidelines commonly use endothelin receptor antagonists (bosentan, ambrisentan, macitentan), PDE-5 inhibitors (sildenafil, tadalafil), sGC stimulator (riociguat), and prostacyclin pathway drugs (epoprostenol, treprostinil, iloprost), alone or in combination. Specialists individualize regimens. PubMed

7) Are there pregnancy risks with PAH drugs?
Yes. The ERAs (bosentan, ambrisentan, macitentan) and riociguat have strong embryo-fetal toxicity warnings and require strict contraception and testing. FDA Access Data+3FDA Access Data+3FDA Access Data+3

8) Can we combine sildenafil and riociguat?
No — contraindicated due to risk of profound hypotension; a washout is required when switching. FDA Access Data

9) Do “stem cell” treatments work?
Not yet proven; no FDA-approved stem-cell therapy for PH. Consider only within regulated clinical trials; avoid commercial clinics. PH Association

10) Will my child need surgery?
Many do need airway surgery (web lysis) and some require cardiac repair depending on anatomy; transplant is a last resort for refractory advanced PH. Medscape+1

11) What is supervised exercise?
A clinician-designed program that gently improves endurance without overloading the right heart; it’s different from unsupervised strenuous activity. smw.ch

12) Why so many follow-ups and tests?
PH can evolve over time; serial echos, labs (for drug safety), and growth checks guide therapy and keep children safe. PubMed

13) Are growth problems inevitable?
Persistent growth deficiency is reported, but careful nutrition, feeding therapy, and control of cardiopulmonary stress can support catch-up growth. PMC

14) What should dentists and anesthetists know?
Warn them early about the airway history and PH; plan anesthesia carefully to avoid airway loss and right-heart stress. orphananesthesia.eu

15) Where can families find support?
Pulmonary Hypertension Association resources (patient-friendly guides), American Lung Association consensus summaries, and specialized PH centers offer education and peer support. PH Association+1

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: November 02, 2025.